Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Abbott Laboratories Yönetim

Yönetim kriter kontrolleri 3/4

Abbott Laboratories' CEO'su Robert Ford, Oct2018 tarihinde atandı, in görev süresi 4.92 yıldır. in toplam yıllık tazminatı $ 23.27M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.4% maaş ve 93.6% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.024% ine doğrudan sahiptir ve bu hisseler CLP 42.90B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.8 yıl ve 5.7 yıldır.

Anahtar bilgiler

Robert Ford

İcra Kurulu Başkanı

US$23.3m

Toplam tazminat

CEO maaş yüzdesi	6.4%
CEO görev süresi	6yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	5.8yrs
Yönetim Kurulu ortalama görev süresi	5.7yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Robert Ford'un ücretlendirmesi Abbott Laboratories'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$6b
Jun 30 2024	n/a	n/a	US$6b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$8b
Jun 30 2022	n/a	n/a	US$9b
Mar 31 2022	n/a	n/a	US$8b
Dec 31 2021	US$25m	US$1m	US$7b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$6b
Dec 31 2020	US$20m	US$1m	US$4b
Sep 30 2020	n/a	n/a	US$3b
Jun 30 2020	n/a	n/a	US$3b
Mar 31 2020	n/a	n/a	US$4b
Dec 31 2019	US$12m	US$1m	US$4b
Sep 30 2019	n/a	n/a	US$3b
Jun 30 2019	n/a	n/a	US$3b
Mar 31 2019	n/a	n/a	US$3b
Dec 31 2018	US$8m	US$784k	US$2b
Sep 30 2018	n/a	n/a	US$802m
Jun 30 2018	n/a	n/a	US$812m
Mar 31 2018	n/a	n/a	US$365m
Dec 31 2017	US$5m	US$675k	US$344m

Tazminat ve Piyasa: Robert 'nin toplam tazminatı ($USD 23.27M ), CL pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.68M ).

Tazminat ve Kazançlar: Robert 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Robert Ford (50 yo)

6yrs

Görev süresi

US$23,268,171

Tazminat

Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Ford	Chairman of the Board	6yrs	US$23.27m	0.024% CLP 47.5b
Philip Boudreau	CFO & Executive VP of Finance	1.1yrs	US$3.32m	0.0023% CLP 4.5b
Hubert Allen	Executive VP	11.8yrs	US$7.42m	0.011% CLP 21.0b
Daniel Salvadori	Executive VP and Group President of Established Pharmaceuticals & Nutritional Products	10.1yrs	US$5.93m	0.0072% CLP 14.3b
Lisa Earnhardt	Executive VP & Group President of Medical Devices	5.8yrs	US$5.50m	0.0035% CLP 7.0b
Sabina Ewing	Senior VP of Business & Technology Services and Chief Information Officer	less than a year	Veri yok	Veri yok
Michael Comilla	Vice President of Investor Relations.	no data	Veri yok	Veri yok
Erica Battaglia	VP and Chief Ethics & Compliance Officer	no data	Veri yok	Veri yok
Melissa Brotz	Vice President of Public Affairs & Corporate Marketing	no data	Veri yok	Veri yok
Christopher Scoggins	Senior Vice President of Commercial Operations	1.8yrs	Veri yok	Veri yok
Mary Moreland	Executive Vice President of Human Resources	5.2yrs	Veri yok	0.0059% CLP 11.7b
Jared Watkin	Executive Vice President of Diabetes Care	9.3yrs	Veri yok	0.0041% CLP 8.2b

5.8yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: ABTCL 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Robert Ford	Chairman of the Board	4.9yrs	US$23.27m	0.024% CLP 47.5b
Daniel Starks	Independent Director	7.7yrs	US$349.29k	0.39% CLP 762.8b
John Stratton	Independent Director	7.8yrs	US$341.96k	0.00020% CLP 395.6m
Nancy McKinstry	Lead Independent Director	12.8yrs	US$405.96k	0.00027% CLP 534.1m
Michael Roman	Independent Director	3.5yrs	US$337.96k	0% CLP 0
Robert Alpern	Independent Director	16yrs	US$441.44k	0% CLP 0
Michael O'Grady	Independent Director	1.5yrs	US$283.96k	0% CLP 0
Michelle Kumbier	Independent Director	6.3yrs	US$331.96k	0.00018% CLP 356.0m
Sally Blount	Independent Director	12.8yrs	US$362.60k	0.00015% CLP 296.7m
Claire Babineaux-Fontenot	Independent Director	2.1yrs	US$354.96k	0% CLP 0
Darren McDew	Independent Director	5.1yrs	US$331.19k	0% CLP 0
Patricia Gonzalez	Independent Director	3.2yrs	US$356.96k	0% CLP 0

5.7yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ABTCL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.7 yıldır).

Abbott Laboratories Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insider recently sold CL$2.9m worth of stock

Insider recently sold CL$2.3b worth of stock

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Insider recently sold CL$111m worth of stock

Independent Director recently sold CL$4.4b worth of stock

Recent updates

Third quarter 2024 earnings released: EPS: US$0.94 (vs US$0.82 in 3Q 2023)

Abbott Laboratories Provides Earnings Guidance for the Fourth Quarter and Full Year of 2024

Abbott Advances Pulsed Field Ablation Clinical Studies and Launches New Technology to Support Advanced Cardiac Mapping

Upcoming dividend of US$0.55 per share

Abbott Laboratories to Report Q3, 2024 Results on Oct 16, 2024

Second quarter dividend of US$0.55 announced

Insider recently sold CL$2.9m worth of stock

Abbott Initiates Clinical Study to Evaluate the Use of Its Deep Brain Stimulation System to Manage Severe Depression

Second quarter 2024 earnings released: EPS: US$0.74 (vs US$0.79 in 2Q 2023)

Abbott Laboratories Provides Earnings Guidance for the Third-Quarter 2024

Upcoming dividend of US$0.55 per share

Abbott Laboratories(NYSE:ABT) dropped from Russell 1000 Growth-Defensive Index

Abbott Laboratories to Report Q2, 2024 Results on Jul 18, 2024

Purchasers of Certain PediaSure Products in California May Have Their Rights Affected by a Class Action Lawsuit

First quarter dividend of US$0.55 announced

Abbott Teams Up with the National Association of Community Health Centers to Expand Access to Nutritious Food and Improve Health

Abbott Laboratories Declares Quarterly Common Dividend, Payable on August 15, 2024

Insider recently sold CL$2.3b worth of stock

First quarter 2024 earnings released: EPS: US$0.70 (vs US$0.76 in 1Q 2023)

First quarter 2024 earnings released: EPS: US$0.70 (vs US$0.75 in 1Q 2023)

Abbott Laboratories Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Upcoming dividend of US$0.55 per share

Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside

Abbott Receives FDA Approval for Triclip™, First-Of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve

Abbott Laboratories to Report Q1, 2024 Results on Apr 17, 2024

Abbott Laboratories, Annual General Meeting, Apr 26, 2024

Abbott Announces Real-World Data Show Freestyle Libre Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes

Insider recently sold CL$111m worth of stock

Fourth quarter dividend of US$0.55 announced

Abbott Declares Quarterly Cash Dividend, Payable on May 15, 2024

FDA Advisory Committee Votes in Favor of Abbott's First-Of-Its-Kind TriClip System to Treat People with a Leaky Tricuspid Heart Valve

Now 30% overvalued after recent price rise

Abbott Laboratories Announces the Launch of Its New PROTALITY Brand

Abbott Launches Smallest Rechargeable System with Remote Programming Capabilities to Treat Movement Disorders

Full year 2023 earnings released: EPS: US$3.27 (vs US$3.94 in FY 2022)

Abbott Laboratories Provides Earnings Guidance for the Full Year 2024

Abbott Laboratories Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

Abbott Laboratories Announces Quarterly Dividend Payable on Feb. 15, 2024

Abbott Announces New Late-Breaking Data That Show Advanced Heart Failure Patients Living with its HeartMate 3 Heart Pump

Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes

Abbott Laboratories Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

Independent Director recently sold CL$4.4b worth of stock

Abbott Announces Late-Breaking Data from the LIFE-BTK Clinical Trial Evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves

Third quarter 2023 earnings released: EPS: US$0.82 (vs US$0.81 in 3Q 2022)

Abbott Laboratories Provides Earnings Guidance for the Full Year 2023

Upcoming dividend of US$0.51 per share at 2.1% yield

Abbott Laboratories to Report Q3, 2023 Results on Oct 18, 2023

Abbott Laboratories (NYSE:ABT) acquired Bigfoot Biomedical, Inc..

Abbott Declares Quarterly Dividend, Payable on November 15, 2023

Canadian First - Abbott's Tactiflex™ Ablation Catheter Used to Treat Afib

Abbott Laboratories (NYSE:ABT) entered into definitive agreement to acquire Bigfoot Biomedical, Inc.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş